NCT06262321 (DRO2301) is a Phase 2 clinical trial of Prophylactic Palliative Radiotherapy in Stage 4 NSCLC, sponsored by University of Rochester.

Who is sponsoring NCT06262321?

NCT06262321 is sponsored by University of Rochester.

What drugs are being tested in NCT06262321?

Interventions in NCT06262321: Prophylactic Palliative Radiotherapy.

What condition does NCT06262321 study?

NCT06262321 studies Stage 4 NSCLC, Radiotherapy.

Is NCT06262321 still recruiting?

NCT06262321 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT06262321: DRO2301

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

Recruiting now Phase 2 Last updated 8 September 2025

What this trial tests

Phase 2 trial testing Prophylactic Palliative Radiotherapy in Stage 4 NSCLC in 48 participants. Currently enrolling.

Timeline

15 May 2024

Primary endpoint
1 February 2029

1 February 2029

Quick facts

Lead sponsor	University of Rochester
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	15 May 2024
Primary completion	1 February 2029
Estimated completion	1 February 2029
Sites	1 location across United States

Drugs / interventions tested

Prophylactic Palliative Radiotherapy

Conditions studied

Stage 4 NSCLC — all drugs for Stage 4 NSCLC →
Radiotherapy — all drugs for Radiotherapy →

Sponsor

University of Rochester

Who can join

18 and older, any sex, with Stage 4 NSCLC or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06262321 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06262321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing